Durable efficacy of certolizumab pegol dosed at 400 mg every two weeks over 128 weeks in patients with plaque psoriasis enrolled in three phase 3 trials (CIMPASI-1, CIMPASI-2, and CIMPACT)

被引：0

作者：

Gordon, Ken ^{[1
]}

Warren, Richard B. ^{[2
]}

Gottlieb, Alice B. ^{[3
]}

Blauvelt, Andrew ^{[4
]}

Thaci, Diamant ^{[5
]}

Poulin, Yves ^{[6
]}

Boehnlein, Marion ^{[7
]}

Brock, Fiona ^{[7
]}

Arendt, Catherine ^{[7
]}

Reich, Kristian ^{[8
,9
]}

机构：

[1] Med Coll Wisconsin, Dept Dermatol, Milwaukee, WI 53226 USA

[2] Univ Manchester, Manchester, Lancs, England

[3] Icahn Sch Med Mt Sinai, New York, NY 10029 USA

[4] Oregon Med Res Ctr, Portland, OR USA

[5] Inst & Comprehens Ctr Inflammat Med, Lubeck, Germany

[6] Hop Hotel Dieu, Paris, France

[7] UCB Pharma, Brussels, Belgium

[8] Univ Med Ctr Hamburg Eppendorf, Ctr Translat Res Inflammatory Skin Dis, Inst Hlth Serv Res Dermatol & Nursing, Hamburg, Germany

[9] Skinflammat Ctr Hamburg, Inst Hlth Serv Res Dermatol & Nursing, Hamburg, Germany

来源：

关键词：

D O I：

暂无

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

15001

引用

页码：AB139 / AB139

页数：1